The health problems caused by the frequent relapse of papillary thyroid carcinoma (PTC) remain a worldwide concern since the morbidity rate of PTC ranks the highest among thyroid cancers. Residues from contralateral central lymph node metastases (con-CLNM) are the key reason for persistence or recurrence of unilateral papillary thyroid carcinoma (uni-PTC); however, the ability to assess the status of con-CLNM in uni-PTC patients is limited. To clarify the risk factors of con-CLNM, a total of 250 patients with uni-PTC who underwent total thyroidectomy and bilateral central lymph node dissection were recruited in this study. We compared the clinical, sonographic, and pathological characteristics of patients with con-CLNM to those without con-CLNM and established a nomogram for con-CLNM in uni-PTC. We found that male sex, without Hashimoto’s thyroiditis, present capsular invasion, with ipsilateral lateral lymph node metastases, and the ratio of ipsilateral central lymph node metastases ≥0.16 were independent con-CLNM predictors of uni-PTC (ORs: 2.797, 0.430, 2.538, 2.202, and 26.588; 95% CIs: 1.182–6.617, 0.211–0.876, 1.223–5.267, 1.064–4.557, and 7.596–93.069, respectively). Additionally, a preoperative nomogram for the prediction of con-CLNM based on these risk factors showed good discrimination (C-index 0.881; 95% CI: 0.840–0.923; sensitivity 85.3%; specificity 76.0%) and good agreement via the calibration plot. Our study provided a way to quantitatively and accurately predict whether con-CLNM occurred in patients with uni-PTC, which may guide surgeons to evaluate the nodal status and perform tailored therapeutic central lymph node dissection.
Hashimoto’s thyroiditis is the most common endocrine disorder, with diagnosis primarily relying on serum thyroid autoantibodies and ultrasound feature. However, the diagnostic accuracy of serum thyroid autoantibodies and ultrasound for Hashimoto’s thyroiditis remains unclear. This study enrolled 24,014 participants, including 6,195 (25.8%) patients diagnosed with Hashimoto’s thyroiditis. The diagnostic performance of ultrasound and serum thyroid autoantibodies was assessed against histopathological findings. Both serum thyroid autoantibodies and ultrasound demonstrated high overall specificity (91.8%, 89.8%, and 92.1%, respectively) and negative predictive value (87.4%, 86.9%, and 86.0%, respectively) for diagnosing Hashimoto’s thyroiditis. Additionally, thyroid autoantibodies level was strongly correlated with the risk of Hashimoto’s thyroiditis. However, these methods demonstrated low independent sensitivity (30.5%, 28.5%, and 22.9%, respectively) and positive predictive value (43.7%, 32.4%, and 28.5%, respectively). Furthermore, the combined use of these methods resulted in a notably low sensitivity of 33.6%, despite a relatively low false positive rate of 11.9%. Elevated thyroid autoantibodies strongly correlate with Hashimoto’s thyroiditis risk. While both autoantibodies and ultrasound demonstrate high specificity and negative predictive value, their low independent sensitivity and positive predictive value limit reliability. Combined use reduces false positives but further diminishes sensitivity.
Background: Hashimoto’s thyroiditis (HT) has been associated with papillary thyroid cancer (PTC), yet whether the clinicopathological features of PTC are affected by HT remains unknown. The purpose of this study was to investigate the association of HT with clinicopathological features of PTC. Methods: We conducted a multicenter cross-sectional study to retrospectively evaluate the association of HT with clinicopathological features of PTC in the central provinces of China. The association between HT with clinicopathological features of PTC (including pathological HT and clinical HT) was evaluated by logistic regression analysis. Results: A total of 15,305 patients with PTC were enrolled to this study, with a median age of 42 years at diagnosis, including 11,465 women (74.9%) and 3,840 men (25.1%). The overall prevalence of HT in PTC patients was 22.9% (3,505/15,305). Compared with PTC patients without HT, pathological HT was a potential protective factor for several aggressive characteristics of PTC, including BRAFV600E mutation (P<0.001), extrathyroidal extension (P=0.04), larger primary tumor size (P<0.001), advanced primary tumor stage (P5 (P=0.006), whereas this effect was not observed in clinical HT except for the BRAFV600E mutation and bilateral tumors (P<0.001 for both). Notably, both pathological (P<0.001) and clinical HT (P=0.04) are potential risk factors for multifocal tumors. Conclusions: PTC patients often have concomitant HT. Some potential links between the 2 entities are present. Pathological HT is a potential protective factor for some aggressive characteristics of PTC, whereas this effect does not present in clinical HT, which has guiding significance for clinical treatment decision-making.
25 March 2025 in World Journal of Surgical Oncology
Accurate preoperative evaluation for metastatic lesions is significant for PTC patients. However, the stratification systems revealed inconsistencies in the ultrasound (US) features of cervical metastatic lymph nodes (LNs). This study aimed to investigate and develop a risk stratification model based on US radiologic features for cervical metastatic lesions in PTC patients. This study retrospectively enrolled 1806 LNs from 1665 PTC patients who underwent US-guided fine-needle aspiration biopsy for cervical LNs from January 2010 to December 2022. Univariable and multivariable logistic regression analyses determined and developed the independent risk US features and a risk stratification model for cervical metastatic LNs. The performance of the risk stratification model was assessed and validated by the Korean Society of Thyroid Radiology and the European Thyroid Association. Among the 1806 LNs, 1411 LNs were pathologically diagnosed with malignant. Multivariate analysis indicated that the absence of fatty hilum, cystic components, round shape (SD/LD ≥ 0.5), abundant vascularity, hyperechogenicity (including hyper and hypo-echogenicity, and hyper-echogenicity), and calcifications (include microcalcification, and macrocalcification) were independent risk US features associated with malignant LNs. A risk stratification model for cervical metastatic LNs was developed based on these suspicious US features and showed well-predicted performance (C-index 0.840; 95% CI: 0.840–0.923). Our study proposed a new risk stratification system based on US radiologic features to predict cervical metastatic lymph nodes in PTC patients. We identified several risk factors for lymph node (LN) metastasis from PTC including the absence of fatty hilum, cystic components, round shape (SD/LD ≥ 0.5), abnormal vascularity, hyper-echogenicity, hyper- and hypo-echogenicity, microcalcification, and macrocalcification. These features could serve as valuable indicators for surgeons to accurately assess the status of cervical LNs.
Objective: To analyze the temporal trends and turning points of thyroid cancer burden in China from 1990 to 2021 and project future incidence and mortality to 2035. Study Design: Cross‐sectional study. Setting: Data were sourced from the Global Burden of Disease 2021 database. Methods: Temporal trends were evaluated using Joinpoint regression, and associations between cancer burden and sociodemographic indices were explored through frontier analysis. A Bayesian Age‐Period‐Cohort model was applied to project future disease burden through 2035. Results: In 2021, China reported 48,104 new thyroid cancer cases and 7692 deaths. From 1990 to 2021, the age‐standardized incidence rate (ASIR) and prevalence rate (ASPR) increased markedly (average annual percentage change [AAPC]: 2.98% and 2.25%, respectively), whereas the age‐standardized mortality rate (ASMR) and disability‐adjusted life year rate (ASDR) declined (AAPC: −0.65% and −0.56%). A pivotal shift occurred around 2005: while ASMR and ASDR continued to decrease in both China and globally, China's ASIR and ASPR accelerated further, contrasting with a global deceleration. Projections indicate that China's ASIR for thyroid cancer is expected to increase more rapidly than the global average over the next 15 years. Conclusion: The thyroid cancer burden in China is characterized by rapidly rising incidence and stagnating mortality decline, a pattern distinct from global trends and likely driven by intensified detection. This escalating burden necessitates public health strategies focused on optimizing screening practices and managing overdiagnosis.